July 24, 2025
Envol Biomedical’s neurosurgery team is setting a new standard in NHP translational research through expert surgical techniques, advanced neurotechnologies, and seamless study execution.
A Spotlight on Innovation: Envol Biomedical’s Neurosurgery Collaboration
In the competitive world of translational research, success hinges on precision, innovation, and collaboration. Envol Biomedical has exemplified all three to elevate the standard for nonhuman primate (NHP) neurosurgery models. In its partnership with Endpoint Preclinical, Envol has built a powerhouse team combining clinical and preclinical expertise to develop highly refined central nervous system (CNS) procedures—ultimately helping sponsors reach confident decisions faster.
This collaboration, led by Dr. Reinier Espinosa at Envol Biomedical and Eric Adams, MS, SRS at Endpoint, provides clients with end-to-end solutions for CNS-targeted therapies, including dosing, intrathecal infusion, and routine or complex cerebrospinal fluid (CSF) collection.
Building Better Models: From Clinical Insight to Preclinical Execution
At the heart of this initiative is a shared philosophy: that preclinical models should be translationally relevant, technically feasible, and scientifically robust. Envol has achieved this by bringing together clinical neurosurgical expertise and NHP model development under one roof.
A key example of this alignment began when a sponsor approached Envol with challenges related to intrathecal catheter placement for serial CSF sampling. Eric from Endpoint was brought in to evaluate the situation. While the original surgical technique was sound, refinements to catheter placement led to improved consistency and sample recovery. Within days, multiple NHPs were back online and contributing valuable data—showcasing the impact of applied expertise.
Seamless for Sponsors, Strategic for Science
What makes this collaboration unique is the seamless integration of advanced capabilities without complicating the sponsor experience. Clients work directly with Envol, but benefit from the embedded support and surgical specialization of Endpoint. This allows for streamlined project planning, faster resolution of technical challenges, and improved study outcomes.
“Our clients don’t experience delays or confusion because they’re working with one unified team,” noted Rainier. “We’re constantly iterating together to deliver solutions, whether that means refining a catheter system or designing a completely novel surgical approach.”
Competitive Advantage in a High-Stakes Field
When it comes to intrathecal dosing, CNS delivery, and implantable device models in NHPs, only a handful of CROs can compete.
Envol aims to carve out market share by focusing on:
- High retention and function of surgical implants
- Rapid response and problem-solving during active studies
- Access to elite surgical talent with real-time training capabilities
- A culture of continuous refinement and internal R&D
The team’s ability to not only perform complex surgeries, but to also train supporting personnel and iterate on technique, sets them apart in a field where execution defines credibility.
Specialized Therapeutic Models and Technologies
Beyond case-by-case consulting, Envol supports development across a range of therapeutic areas—particularly in:
- Gene therapy and oligonucleotide delivery
- Pain and neuropharmacology models
- Intrathecal and ICD (intracisternal) infusion studies
- Dorsal Root Ganglion (DRG) injections
Projects like Envol’s novel CLFM implant—a proprietary device successfully placed in NHPs for the first time—underscore the team’s forward-looking innovation. Imaging techniques (e.g., MRI guidance) are often employed to ensure optimal placement and validate surgical outcomes.
“These aren’t off-the-shelf procedures,” Eric explained. “They require precision, planning, and people who understand both the surgical and therapeutic sides of the equation.”
Commitment to Competency: The True Differentiator
While specific technologies and services are critical, Envol’s leadership stresses that competency is the ultimate competitive edge. “It’s not just that we offer these services,” Jake emphasized. “It’s that we ensure our people are trained to the highest standards—and that every capability is delivered with accountability, transparency, and surgical excellence.”
With tight timelines, complex sponsors, and growing demand for targeted CNS delivery, this commitment to quality is what makes Envol Biomedical a preferred partner for cutting-edge biotech firms.
Looking Ahead: Expanding What’s Possible in NHP Neuroscience
As new therapeutics demand novel delivery methods and smarter preclinical validation, Envol Biomedical continues to invest in the future. Their neurosurgery team—bolstered by Endpoint’s expertise—is actively exploring additional use cases, from DRG gene therapy models to more advanced CNS pharmacology applications.
For sponsors seeking a partner that blends expertise with innovation, Envol offers not just a vendor, but a true scientific collaborator.